Refractory Acute Myeloid Leukemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Recruiting
  • Acute Bilineal Leukemia
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-05
Apr 5, 2022
N
Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
  • +6 more
2022-03-31
Mar 31, 2022
N
Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
2022-03-25
Mar 25, 2022
N
Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Los Angeles, California
  • +3 more
2022-03-25
Mar 25, 2022
M
Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +5 more
  • Akt/ERK Inhibitor ONC201
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-10
Mar 10, 2022
N
Recruiting
  • Previously Treated Myelodysplastic Syndrome
  • +7 more
  • Duarte, California
  • +10 more
2022-03-22
Mar 22, 2022
M
Active, not recruiting
  • FLT3 Gene Mutation Negative
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-18
Mar 18, 2022
B
Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Portland, Oregon
  • +1 more
2022-03-18
Mar 18, 2022
F
Recruiting
  • Recurrent Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-07
Mar 7, 2022
C
Recruiting
  • Refractory Acute Myeloid Leukemia
  • +2 more
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
2022-03-15
Mar 15, 2022
M
Active, not recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
M
Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
W
Withdrawn
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Cytokine-induced memory-like NK cells
  • +4 more
  • (no location specified)
2022-02-23
Feb 23, 2022
M
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022
C
Active, not recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
C
Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-21
Feb 21, 2022
F
Recruiting
  • Acute Lymphoblastic Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-25
Feb 25, 2022
R
Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2022-02-25
Feb 25, 2022
M
Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Oxidative Phosphorylation Inhibitor IACS-010759
  • Pharmacological Study
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022
C
Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Comprehensive Cancer Center
2022-02-08
Feb 8, 2022
F
Recruiting
  • Advanced Hematologic Malignancy
  • +4 more
  • Boston, Massachusetts
  • +4 more
2022-02-07
Feb 7, 2022
M
Recruiting
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-08
Feb 8, 2022